GLPwatch
Papers (12034)
Page 197 of 201, ranked by citation count.
- [Changes in weight and diabetes compensation (HbA1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBYII study (observations lasting 24 months)].
- American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery.
- Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students.
- In brief: Removal of suicidality warning from GLP-1 Agonists for weight management.
- A cardiovascular indication for oral semaglutide (Rybelsus).
- [Obesity as a chronic disease: the key role of new therapies].
- Oral semaglutide (Wegovy) for weight loss.
- Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome.
- Semaglutide use in a patient with a long-term ileostomy: A case report highlighting clinical risks and evidence gaps.
- European Society of Cardiology 2018.
- Association of tirzepatide with erectile dysfunction in people with type 2 diabetes.
- 9.4-T MRI monitoring of early MASH progression and therapeutic response in a prefibrotic mouse model.
- Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.
- GLP-1 receptor agonist therapy before bariatric surgery: Effects on weight loss and body composition in clinical practice.
- liraglutide (SAXENDA⁰) and obesit. Still no satisfactory weight loss drugs.
- The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.
- Psychometric Validation of the Simplicity of Diabetes Treatment Questionnaire (Sim-Q) for Type 2 Diabetes.
- Semaglutide (Wegovy) for MASH.
- Comparison table: Some drugs for weight management.
- Assessment of cardiovascular event reduction with SGLT2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes mellitus.
- [The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy].
- Exenatide dosing in alpacas.
- Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss.
- Exenatide attenuates neuroinflammation and rescues sepsis-induced depressive behavior and cognitive dysfunction in a mouse model.
- Lead-guided prodrug development of small molecules as GLP-1R agonists.
- Semaglutide for Weight Loss: Was It Worth the Weight?: Erratum.
- Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes.
- The role of combination therapy in type 2 diabetes in the post-ACCORD era.
- An analysis of dosage volume for halfway doses in the Victoza Pen.
- Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis.
- Obesity Management: Pharmacotherapy.
- Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study.
- The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review.
- GLP-1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta-Analysis.
- GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.
- Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.
- [Basal insulin glargine-lixisenatide fixed ratio combination (Suliqua®)].
- [Current and future medical treatments for metabolic dysfunction-associated steatohepatitis].
- Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation.
- Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling.
- <i>Letter:</i> Tirzepatide in Type 1 Diabetic Obese Patient Using Hybrid Closed-Loop.
- Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity: <i>A Cross-Sectional Survey in Jeddah, Saudi Arabia</i>.
- Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
- Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes.
- Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability.
- [Role of exendin-4 in cardiovascular diseases].
- Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.
- Prospective Comparative Analysis of Synchronous Abdominoplasty and Mastopexy in Bariatric and Nonbariatric Massive Weight Loss Patients: Highlighting the Rising Trend of GLP-1 Analog Use.
- Revolutionising CKD care: semaglutide's kidney-protective leap in type 2 diabetes and chronic kidney disease.
- Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth.
- Correction: Weight loss efficiency and safety of tirzepatide: A Systematic review.
- Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge.
- Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery.
- The GLP-1 Agonist Exenatide Is Associated with Improved Adherence to Health Behavior and Lifestyle Treatment in Adolescents with Obesity: A Randomized Controlled Trial.
- [Treatment of type 2 diabetes: Exenatide or liraglutide? - Exenatide and liraglutide in head-to-head comparison approximately coequal].
- Exendin-4 improves high glucose-induced mitochondrial dysfunction of pancreatic β-cells via PKA/Drp1 signaling.
- Comparison chart: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes.
- Is There a Better Day of the Week to Administer Semaglutide or Tirzepatide? A Systematic Literature Review.
- Noninsulin drugs for type 2 diabetes.
- In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y.